Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Oruka Therapeutics, Inc. has received an average rating of "Buy" from ten brokerages, with a consensus price target of $40.37.
• Institutional investors hold 56.44% of Oruka Therapeutics' stock, with significant increases in holdings from firms like Fairmount Funds Management and Franklin Resources.
• The company reported an EPS of ($0.46) in its last quarterly earnings, exceeding analysts' expectations, while predicting an average EPS of ($3.41) for the current fiscal year.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have earned an average recommendation of "Buy" from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $40.3750.

Several equities analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. BTIG Research began coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating for the company. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 18th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Fairmount Funds Management LLC boosted its holdings in Oruka Therapeutics by 5.0% in the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock valued at $65,382,000 after acquiring an additional 160,000 shares during the last quarter. VR Adviser LLC raised its holdings in shares of Oruka Therapeutics by 6.5% in the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock worth $63,708,000 after purchasing an additional 200,000 shares during the period. RTW Investments LP raised its holdings in shares of Oruka Therapeutics by 5.1% in the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after purchasing an additional 95,001 shares during the period. Braidwell LP lifted its stake in shares of Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company's stock valued at $16,133,000 after purchasing an additional 424,750 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Oruka Therapeutics by 40.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company's stock worth $11,355,000 after purchasing an additional 292,421 shares during the period. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $15.56 on Wednesday. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The company has a market capitalization of $582.72 million, a price-to-earnings ratio of -5.54 and a beta of -0.26. The stock has a fifty day moving average of $14.01 and a two-hundred day moving average of $11.74.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. On average, analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.